<?xml version="1.0" encoding="UTF-8"?>
<p id="p0165">Despite the ability of enhancing Th2 
 <italic>via</italic> IL-33 in DCs [
 <xref rid="bb0435" ref-type="bibr">87</xref>], it has been described that IVIg modulates the balance between CD4
 <sup>+</sup>/CD8
 <sup>+</sup> T cells, as well as promoting proliferation and survival of Tregs. Treatment with IVIg seems to reduce antigenic presentation of T cells 
 <italic>via</italic> the modulation and inhibition of DCs. This process was independent of FCÎ³RIIB [
 <xref rid="bb0455" ref-type="bibr">91</xref>], and other reports showed that reduced activation of T cells was independent of IgG sialylation, monocytes or B cells [
 <xref rid="bb0460" ref-type="bibr">92</xref>].
</p>
